Category Archives: Drug

Peek inside a lab trying to create living medicine

For the second episode of “Science Happens,” we hung out with Pamela Silver, a scientist who wants to hack the microbiome.The microbiome — those trillions of bacteria that occupy our bodies — has become an obsession for many scientists in recent years. They are using powerful DNA-sequencing technologies to catalog the thousands of species that live in us and on us. Those experiments are revealing just how much we depend on the microbiome for our well-being. Our inner ecosystem turns out to help us digest food, influence our metabolism, nurture … Read more

Top 15 private biotech companies of 2015

rnai-technoogy-cancer-cure

Alector: “We are developing drug leads against unique, genetically-validated neuro-immune targets through a novel, hypothesis-driven approach to neurodegeneration. We thankFierceBiotech for recognizing the potential of our strategy,” said Arnon Rosenthal, co-founder, president and CEO of Alector. Release

Arvinas: “We are thrilled to be selected by FierceBiotech to be among the top private biotech firms globally,” Manuel Litchman, president and chief executive officer of Arvinas, said. “This award recognizes the dedication of our employees, our founder, Dr. Craig Crews, and our partners to bring our PROTAC technologies to patients with … Read more

Cellectis – CAR T-Cell Therapy

All you need to know about Cellectis :

4 branchs :

-Oncology
-Sceil
-Cellectis Bioresearch
-Cellectis Plants Science (CPS)

Corporate presentation : urlz.fr/1AWL


http://www.capitalpress.com/Nation_World/Nation/20141125/new-gmo-potato-avoids-usda-regulation

< ![if !IE]>< ![endif]>

http://sceil.com/
http://www.ascrnetwork.com/index.php?option=com_content&view=article&id=3014:cellectis-bioresearch-inc-wins-a-69-million-contract-with-the-national-institutes-of-health-on-ips-cells&catid=102

http://infocampo.com.ar/nota/campo/67136/cellectis-plant-sciences-una-emergente-que-puede-revolucionar-el-mejoramiento-vegetal

http://www.cellectis.com/en/content/cellectis-step-towards-new-therapy-aids-cellectis-publishes-genome-engineering-advance

http://www.nature.com/srep/2015/150130/srep08150/full/srep08150.html… Read more

non-small cell lung cancer got FDA approval

nullBristol-Myers Squibb ($BMY) picked up FDA approval to use its new oncology treatment in lung cancer, significantly boosting the value of a therapy already expected to bring in billions each year.

The FDA’s latest approval of Opdivo, already cleared for melanoma, comes just days after the agency accepted Bristol-Myers’ application and more than three months ahead of schedule. Bristol-Myers’ treatment is designed to galvanize an immune system attack on tumors by blocking a pathway called PD-1, which, left unchecked, allows cancer cells to pass undetected by the body’s natural defenses.… Read more